1. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Issue 11 (7th April 2006) Authors: Van Assche, G; Sandborn, W J; Feagan, B G; Salzberg, B A; Silvers, D; Monroe, P S; Pandak, W M; Anderson, F H; Valentine, J F; Wild, G E; Geenen, D J; Sprague, R; Targan, S R; Rutgeerts, P; Vexler, V; Young, D; Shames, R S Journal: Gut Issue: Volume 55:Issue 11(2006) Page Start: 1568 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P390 Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study. (16th January 2018) Authors: Herfarth, H; Barnes, E L; Jackson, S; Valentine, J F; Hanson, J; Higgins, P D R; Isaacs, K L; Osterman, M T; Sands, B E; Lewis, J D Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S300 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Issue 10 (7th June 2009) Authors: Valentine, J F; Fedorak, R N; Feagan, B; Fredlund, P; Schmitt, R; Ni, P; Humphries, T J Journal: Gut Issue: Volume 58:Issue 10(2009) Page Start: 1354 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗